Is LXRX a good stock to buy? We came across a bullish thesis on Lexicon Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on LXRX. Lexicon Pharmaceuticals, Inc.’s share was trading at $1.8800 as of June 9th. LXRX’s trailing P/E was 3.74 according to Yahoo Finance.
Pressmaster/Shutterstock.com
Lexicon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on cardiometabolic and neuropathic diseases, anchored by its sotagliflozin dual SGLT1/SGLT2 platform. The investment thesis is a variant perception that prior regulatory setbacks in type 1 diabetes are over-discounted, with STENO-1 safety data and improved monitoring protocols strengthening the mid-2026 NDA resubmission pathway for Zynquista.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
In type 1 diabetes, sotagliflozin offers dual gut-renal inhibition, improving postprandial glucose control and cardiovascular outcomes versus single-mechanism SGLT2 agents. The pipeline extends beyond diabetes into heart failure and neuropathic pain, with Inpefa providing commercial validation and SONATA-HCM Phase 3 in hypertrophic cardiomyopathy targeting a 2027 readout and approximately $900 million peak sales opportunity.
Additional assets include LX9211 for neuropathic pain and LX9851, partnered with Novo Nordisk, expanding optionality into obesity and metabolic disease. Clinical evidence from SOLOIST-WHF and SCORED supports cardiovascular benefit, while updated STENO-1 and ATTD 2026 data reduce prior ketoacidosis concerns and improve regulatory confidence. Financially, the company holds approximately $220 million in cash, supporting runway into mid-2027 under cost controls and milestone inflows.
The base case assumes execution across type 1 diabetes and HCM, enabling a re-rating toward specialty pharma multiples, while the bull case exceeds $1 billion in revenue by 2030 with a $5.00 price target. Key catalysts include NDA resubmission, HCM readout, and Inpefa commercial traction, making the investment case highly catalyst-driven with significant upside from pipeline optionality and regulatory re-rating potential.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy, gene editing pipeline, and reimbursement-driven commercialization upside. CRSP’s stock price has appreciated by approximately 25.65% since our coverage. BioEquity Watch shares a similar view but emphasizes Lexicon Pharmaceuticals’ regulatory re-rating in type 1 diabetes via sotagliflozin and STENO-1 safety data alongside HCM catalyst optionality growth and pipeline expansion.
Lexicon Pharmaceuticals, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 28 hedge fund portfolios held LXRX at the end of the first quarter which was 20 in the previous quarter. While we acknowledge the risk and potential of LXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LXRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
